PI3K/AKT/mTOR 信号通路在乳腺癌HER2治疗耐药中的作用研究进展

doi:10.11904/j.issn.1002-3070.2014.04.015

PRACTICAL ONCOLOGY JOURNAL ›› 2014, Vol. 28 ›› Issue (4): 360-363.doi: 10.11904/j.issn.1002-3070.2014.04.015

• Review • Previous Articles Next Articles

The research development of PI3K/AKT/mTOR signaling pathway in HER2 resistance for the treatment of breast cancer

MA RuiJin ,YANG Yu

¹ Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086，China

Online:2014-08-28 Published:2014-07-31

Abstract

Abstract: Abstract HER2-targeting therapy is an important part of the treatment for breast cancer with HER2 overexpression. However, the therapy effectiveness is largely influenced by HER2 resistance. Previous studies have confirmed that PI3K/AKT/mTOR signaling pathway is activated during the process of drug resistance to HER2-targeting therapy. Therefore, investigating the PI3K/AKT/mTOR signaling pathway and drugs-targeted pathway is important for the treatment of breast cancer.

Key words: PI3K/AKT/mTOR pathway, HER2 , Breast neoplasms, Targeted therapy

CLC Number:

R730.231

MA RuiJin,YANG Yu. The research development of PI3K/AKT/mTOR signaling pathway in HER2 resistance for the treatment of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 360-363.

[1]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[2]	YAN Shi, HUO Mingming, PANG Hui, LI Yan, CAI Li. Effects of p53 on predictive value for efficacy of endocrine drugs in postoperative postmenopausal breast cancer patients with HR positive and HER-2 positive [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 234-213.
[3]	HUANG Qianqian, MA Jianjia, WU Qiang, LIU Binbin, MU Xiaoqin, LIU Shulin. Research progress on tumor stem cells and tumor targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 533-537.
[4]	WANG Shuo, SONG Yanni. Advances in pathogenesis of breast Paget's disease [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 444-447.
[5]	SUN Yuqi,CHEN Xiuwei. Research progress of CTGF/CCN2 in the development and targeted therapy of malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 363-366.
[6]	ZUO Zhichao, SU Danke, DENG Wenjuan, JIN Guanqiao. Recent advances of ELAM-1 in targeted cancer therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 444-447.
[7]	LV Fulian, GAO Xiang, JIN Aishun. Functional characteristic research progress of DCLK1 as a potential biomarker in cancer stem cells for gastrointestinal onalignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 458-461.
[8]	DU Ge,JIANG Zefei. The application of Lapatinib in breast cancer and its mechanism of drug resistance [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(4): 376-379.
[9]	LIU Enrui,REN Huan,ZHAO Yu,SU Jun. Advanced research on characteristics of the classical subtype of human glioblastoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 136-139.
[10]	YAN Xiaofei,HAN Bo. The treatment and prospects of locally advanced nasopharyngeal carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 149-152.
[11]	LI Sen,LI Zhiguo,CHENG Long,XUE Yingwei. Progress of targeted therapy in Her-2 positive gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 188-192.
[12]	QIU Zidan,LI Jiancheng. Molecular targeted therapy for esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 57-60.
[13]	LUO Jianing,GE Xiaofeng. Drug treatment status and research progress on triple-negative breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 89-92.
[14]	ZHANG Meng,ZHANG Jiewu,KONG Lingyu. The inhibition of skin tumor growth in Galectin-3-deficient mice [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 305-309.
[15]	SONG chunyu,QU guofan. New progress in the study of gene- targeted threapy for osteosacoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(4): 364-366.

The research development of PI3K/AKT/mTOR signaling pathway in HER2 resistance for the treatment of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments